NASDAQ: AFMDAffimed Nv Stock
$0.73+0.00 (+0%)
Updated Apr 17, 2025
AFMD Price
$0.73
Fair Value Price
N/A
Market Cap
$12.03M
52 Week Low
$0.52
52 Week High
$8.95
P/E
-0.15x
P/B
0.66x
P/S
55.52x
PEG
N/A
Dividend Yield
N/A
Revenue
$932.98k
Earnings
-$77.74M
Gross Margin
100%
Operating Margin
-8,005.25%
Profit Margin
-7,978.3%
Debt to Equity
1.32
Operating Cash Flow
-$85M
Beta
1.37
Next Earnings
Jun 9, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AFMD Overview
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AFMD's potential to beat the market
- AFMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AFMD
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important AFMD news, forecast changes, insider trades & much more!
AFMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AFMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AFMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AFMD is good value based on its book value relative to its share price (0.66x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
AFMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AFMD due diligence checks available for Premium users.
Valuation
AFMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
-177.72x
Market
27.98x
AFMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.66x
Industry
4.05x
AFMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AFMD's financial health
Profit margin
Revenue
$172.2k
Net Income
-$16.8M
Profit Margin
-9,767.1%
AFMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AFMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$44.4M
Liabilities
$25.3M
Debt to equity
1.32
AFMD's short-term assets ($34.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AFMD's short-term assets ($34.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AFMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AFMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.4M
Investing
$7.4M
Financing
$1.4M
AFMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AFMD vs Biotech Stocks
Affimed Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.